Business leaders are ambitious about agentic AI but have legitimate concerns about data privacy, security, and compliance.

SESAUA annual meeting featured a bladder cancer session and a presentation by Dr. Meredith Bernhard discussing the oncologic efficacy of reduced versus standard-dose BCG for non muscle invasive ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

The fact that the Chinese Volt Typhoon hackers remained undetected for over 300 days inside a small public utility’s network is concerning due to their extended time within the electric grid, as well ...

Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.

U.S. Urology Partners is one of the first providers to offer patients ImmunityBio’s recombinant Bacillus Calmette-Guérin (rBCG) The FDA recently authorized ImmunityBio’s EAP for rBCG to address U.S.

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

OAE promotes durian peel as high-quality animal feed, driving the BCG economy with Pure Plus Farm as a model community ...

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the ...

Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several ...

Updated clinical & translational results: BOND-003 Cohort C- A phase 3, single-arm study of intravesical cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder ...